Clinical Trials on Leukemia, Chronic Myelogenous (CML)

Total 3361 results

Astex Pharmaceuticals, Inc.
Eisai Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Autoimmune Diseases | Hodgkin Lymphoma | Hematologic Malignancies | Acute Lymphoblastic Leukemia (ALL) | Non-hodgkin Lymphoma | Severe Aplastic Anemia | Inherited Disorders of Metabolism | Inherited Abnormalities of Platelets | Histiocytic Disorders | Acute Myelogenous Leukemia (AML or ANLL) | Other Acute... and other conditions

United States
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)

Lymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Mixed Phenotype Acute Leukemia

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Terminated

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Lymphoma | Leukemia | Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | AML | Acute Myelogenous Leukemia | Hematologic Malignancy | Myeloma | Non-hodgkin's Lymphoma | CLL | ALL

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (MACS0911)

Philadelphia Chromosome Positive | Chronic Myelogenous Leukemia in Chronic Phase

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Therapy-Related Acute Myeloid Leukemia and other conditions

United States
Pfizer
Developmental Therapeutics Consortium

Terminated

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Previously Treated PH + CML

Spain, United States, Austria, Sweden, Germany, France, Italy, Norway
Masonic Cancer Center, University of Minnesota

Terminated

AHN-12 Biodistribution in Advanced Leukemia

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Recurrent Disease | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase of Disease | Chronic Phase of Disease

United States, Germany, Italy
Centre Hospitalier Henri Duffaut - Avignon

Recruiting

Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia (IPA-LMC)

Chronic Myelogenous Leukemia - Chronic Phase

France
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Masonic Cancer Center, University of Minnesota

Withdrawn

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

Acute Myeloid Leukemia | Acute Lymphocytic Leukemia | Chronic Myelogenous Leukemia | Myelodysplasia

United States
Novartis Pharmaceuticals

Recruiting

Asciminib Roll-over Study

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myelogenous Leukemia

Denmark, Spain, France, Germany, Lebanon, Italy, Argentina, Czechia, Portugal, United Kingdom, Brazil, Mexico, Russian Federation, Taiwan, Austria, Canada, Korea, Republic of, Turkey, United States, Singapore, Japan, Bulgaria, Poland, Romani... and more
Emory University

Terminated

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

Leukemia | Chronic Myeloid Leukemia | Chronic Myelogenous Leukemia

United States
University of California, Irvine
United States Department of Defense

Active, not recruiting

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, Refractory

United States
Children's Hospital Medical Center, Cincinnati

Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Lymphoma | Follicular Lymphoma | Leukemia | B Cell Lymphoma | Hodgkin Lymphoma | Burkitt Lymphoma | AML | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | T-cell Lymphoma | Peripheral T Cell Lymphoma and other conditions

United States
Deborah Rund

Completed

Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel

Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | Chronic Myelogenous Leukemia

Israel
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Natural History Study of Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Memorial Sloan Kettering Cancer Center

Completed

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia

Leukemia

United States
Novartis Pharmaceuticals

Terminated

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Russian Federation
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

Myeloproliferative Disorders | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | B Acute Lymphoblastic Leukemia With t(9;22)(q34... and other conditions

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Novartis Pharmaceuticals

Terminated

Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. (ENESTswift)

Philidelphia Positive Chronic Myeloid Leukaemia

Australia
National Cancer Institute (NCI)

Terminated

Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins Lymphoma

United States
Mayo Clinic

Withdrawn

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

B-cell Adult Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United States
Threshold Pharmaceuticals

Completed

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced Myelofibrosis

United States
Baptist Health South Florida

Withdrawn

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies (2019-KOE-001)

Acute Myeloid Leukemia | Hematologic Diseases | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Hematologic Malignancy | Chronic Myelogenous Leukemia

United States
Center for International Blood and Marrow Transplant...
National Marrow Donor Program; Pediatric Blood and Marrow Transplant Consortium

Active, not recruiting

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

Juvenile Myelomonocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplasia | Acute Lymphoblastic Leukemia/Lymphoma

United States
Hospital Universitario Dr. Jose E. Gonzalez
Fernando De la Garza Salazar

Recruiting

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, Chronic Phase

Mexico
Shire

Completed

Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States, Canada
M.D. Anderson Cancer Center

Completed

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

Myelogenous Leukemia, Chronic

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML0206)

Leukemia

Italy
Medical Research Council

Unknown

Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Leukemia

United Kingdom
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

Leukemia

United States
German CML Study Group

Unknown

Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

Germany
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Novartis
National Cancer Institute (NCI)

Completed

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Leukemia

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
EDDC (Experimental Drug Development Centre), A*STAR...
Chiltern International Inc.

Withdrawn

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) | Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)

United States, Singapore
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Singapore, France, Germany, United Arab Emirates, Greece, Italy, Czechia, Hungary, United States, India, Oman, Malaysia, Korea, Republic of, Turkey, Bulgaria, Canada, Slovakia, United Kingdom, Argentina, Jordan, Romania, South Africa and more
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

Thrombocytopenia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13... and other conditions

United States
Grupo Cooperativo de Hemopatías Malignas

Recruiting

Myeloid Mutations Register in R/R CML

Chronic Myeloid Leukaemia Recurrent | Chronic Myeloid Leukemia, in Relapse

Mexico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Leukemia

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Novartis

Completed

STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Leukemia

United States

Clinical Trials on Leukemia, Chronic Myelogenous (CML)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations